Table 2.
Subgroup and sensitivity analysis assessing LAIV efficacy among immunocompromised subjects stratified by influenza serotype. ES: effect size, estimated as odds ratio.
| Analysis | Model | Number of Studies Included | ES | 95% CI | p-Value | Sample Size | I2 | p-Value | Intercept | Tau (t) | p-Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A/H1N1 (control group IIV) | Fixed | 3 | 0.05 | 0.04–0.06 | 0.000 | 3099 | 91.77 | 0.000 | 3.28 | 1.43 | 0.388 |
| Random | 0.29 | 0.02–4.10 | 0.361 | ||||||||
| A/H1N1 (control group TIV or placebo) | Fixed | 5 | 0.05 | 0.04–0.06 | 0.000 | 3397 | 86.82 | 0.000 | 1.58 | 1.02 | 0.383 |
| Random | 0.15 | 0.02–1.08 | 0.059 | ||||||||
| A/H3N2 (control group IIV) | Fixed | 3 | 0.19 | 0.16–0.23 | 0.000 | 3241 | 72.80 | 0.025 | −1.99 | −1.63 | 0.350 |
| Random | 0.13 | 0.06–0.28 | 0.000 | ||||||||
| A/H3N2 (control group IIV or placebo) | Fixed | 4 | 0.19 | 0.17–0.23 | 0.000 | 3292 | 69.9 | 0.021 | −0.61 | −0.42 | 0.713 |
| Random | 0.16 | 0.07–0.35 | 0.000 | ||||||||
| B (control group IIV) | Fixed | 3 | 0.04 | 0.03–0.05 | 0.000 | 3242 | 45.95 | 0.157 | 0.59 | 0.41 | 0.752 |
| Random | 0.05 | 0.01–0.18 | 0.000 | ||||||||
| B (control group IIV or placebo) | Fixed | 4 | 0.04 | 0.03–0.05 | 0.000 | 3294 | 44.27 | 0.146 | 0.89 | 1.01 | 0.418 |
| Random | 0.06 | 0.02–0.22 | 0.000 |